Scalper1 News
Tesaro stock plunged more than 20% in morning trading in the stock market today after the oncology-focused biopharmaceutical company reported drug trial results. The Waltham, Mass.-based company said secondary endpoints for phase III trials of rolapitant were not met, though primary endpoints were met. Rolapitant is being developed to treat chemotherapy-induced nausea and vomiting, or CINV, for cancer patients. The company said it remains on track Scalper1 News
Scalper1 News